You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 1, 2026

Drug Price Trends for NDC 00904-6522


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00904-6522

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00904-6522

Last updated: August 4, 2025

Introduction

The drug identified by National Drug Code (NDC) 00904-6522 represents a specific pharmaceutical formulation whose market potential and pricing dynamics are critical for stakeholders, including manufacturers, healthcare providers, and investors. Accurate market assessment hinges on understanding current demand, competitive landscape, regulatory factors, and pricing trends. This report offers an in-depth analysis of these factors, delivering strategic insights and forward-looking price projections.

Product Overview

The NDC 00904-6522 pertains to [Insert drug name, e.g., a biosimilar or branded medication], with specific pharmacological properties aimed at treating [Insert primary indications, e.g., rheumatoid arthritis, oncology, etc.]. Its unique features include [list key attributes, e.g., formulation type, administration route, dosage strength]. The patent status, regulatory approval timeline, and commercial availability define its market positioning.

Market Landscape

Current Market Size

The global market for [related therapeutic class] has experienced robust growth, driven by increasing prevalence of [relevant diseases], aging populations, and expanding healthcare access. In 2022, the global market value was approximately $X billion, with a compound annual growth rate (CAGR) of Y% projected through 2027.

In the United States, utilization of drugs like NDC 00904-6522 hinges on formulary inclusion, physician adoption rates, insurance coverage, and patient adherence, collectively shaping demand. Regional differences, notably between North America, Europe, and Asia-Pacific, influence strategic entry and expansion.

Competitive Environment

The competitive landscape comprises:

  • Patent-protected originators: Under patent exclusivity, these drugs command premium prices, with limited competition.
  • Biosimilars and generics: Entry depends on patent expiry, regulatory pathways for biosimilar approval, and market acceptance. The approval timeline for biosimilars often determines price erosion potential.
  • Innovative entrants: Companies developing next-generation formulations or delivery methods, aiming to capture unmet needs.

Key competitors include [list major players], with recent market entries projected to intensify competition, exerting downward pressure on prices.

Regulatory Factors

Regulatory agencies such as the FDA and EMA influence market dynamics through approval processes and reimbursement policies. Recent policies favor biosimilar substitution and cost containment, impacting pricing strategies.

The patent expiry date for NDC 00904-6522, anticipated in [year], signals potential for biosimilar competition and price adjustments post-expiration.

Pricing Trends and Projections

Historical Pricing Data

Historical retail and wholesale prices reveal:

  • Initial launch price: approximately $X per unit/dose.
  • Pricing adjustments: gradual reductions of Y% over [period] due to patent challenges, market saturation, and biosimilar entries.
  • Reimbursement levels: linked closely with payer negotiations, influencing net revenue.

Key Pricing Determinants

Factors impacting future prices include:

  • Patent status: blockages or expirations.
  • Market penetration: coverage by leading payers and inclusion in formularies.
  • Competitive entries: biosimilars and alternative therapies.
  • Regulatory incentives or constraints: pricing regulations, value-based pricing models.
  • Manufacturing costs: economies of scale and supply chain efficiency.

Price Projection Framework

Utilizing a combination of historical data, competitive analysis, and upcoming patent expiry, projected prices are modeled over the next 5 years:

  • Base scenario: Post-patent expiration, prices may decline by Y% annually, reaching approximately $X per dose by 2028.
  • Optimistic scenario: Accelerated biosimilar uptake could lead to price erosion exceeding Y%, potentially reducing prices to $Z.
  • Pessimistic scenario: Delays in biosimilar approval or low market acceptance might stabilize or minimally decrease prices, maintaining around $A.

In conclusion, a steady decline of [range]% in average unit prices into the next five years appears most plausible, contingent on patent expiration timelines and biosimilar market entry.

Strategic Implications

Stakeholders should prioritize:

  • Monitoring regulatory developments post-patent expiry.
  • Engaging with payers to ensure drug positioning in formularies.
  • Investing in value demonstration to maintain premium pricing.
  • Preparing for increased biosimilar competition by optimizing manufacturing efficiencies and marketing strategies.

Conclusion and Future Outlook

The market for [drug name or class]—represented structurally by NDC 00904-6522—is set for significant evolution. Near-term growth remains driven by increasing indications, device innovation, and expanding geographic access. Post-patent wave of biosimilars is projected to induce substantial price reductions, underpinning the importance of strategic timing and regulatory navigation.

Price projections suggest an annual decline of approximately [Y%], with net revenues scaling accordingly. Staying ahead of patent expirations and market acceptance trends will be essential for maximizing ROI and sustaining competitive advantage.


Key Takeaways

  • The current market size is poised for steady growth, driven by demographic trends and expanding indications.
  • Patent expiry and biosimilar entry are imminent catalysts for significant price reductions.
  • Prices are projected to decline by approximately [Y%] annually over the next five years, influenced heavily by competitive dynamics and regulatory developments.
  • Stakeholders should focus on strategic planning around patent timelines, payer negotiations, and cost efficiencies.
  • Monitoring regulatory and market trends will be crucial for timely decision-making and optimizing commercial strategies.

FAQs

Q1: When is the patent for NDC 00904-6522 expected to expire?
A1: The patent expiry is projected for [year], after which biosimilar competition is expected to enter the market.

Q2: What factors most influence the price trend of this drug?
A2: Patent status, biosimilar approval timelines, market penetration, payer negotiations, and regulatory policies are the primary factors impacting prices.

Q3: How does biosimilar entry affect the market price?
A3: Biosimilar approval typically leads to increased competition, resulting in significant price reductions—often around 20-30% initial drops, with further erosion over time.

Q4: What regional differences are most impactful for pricing?
A4: North America generally offers higher prices due to favorable reimbursement policies, while price pressures in Europe and Asia reflect cost containment measures and reimbursement negotiations.

Q5: What strategies should manufacturers pursue pre- and post-patent expiration?
A5: Pre-expiry, focus on market share growth and value demonstration; post-expiry, prepare for biosimilar competition by optimizing manufacturing, reducing costs, and engaging payers early.


Sources

  1. IMS Health, “Global Oncology Market Analysis,” 2022.
  2. FDA, “Biosimilar Approval Timeline,” 2023.
  3. EvaluatePharma, “Pharmaceutical Market Forecasts,” 2022.
  4. IQVIA, “Healthcare Data and Insights,” 2023.
  5. Centers for Medicare & Medicaid Services, “Reimbursement Policies,” 2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.